Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03530397 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
A Phase 1 study of Selected Advanced Solid Tumors, sponsored by MedImmune.
- Active
- Registry status
- Phase 1
- Development phase
- 401
- Enrollment target
- 20
- Study locations
NCT03530397 is a Phase 1 study of Selected Advanced Solid Tumors that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 401 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT03530397, a Phase 1 study of Selected Advanced Solid Tumors, is active but no longer recruiting, sponsored by MedImmune.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 401 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- BIOLOGICAL MEDI5752
- DRUG Paclitaxel or Nab-Paclitaxel
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Melbourne
- Research Site - Randwick
- Research Site - Bordeaux
- Research Site - Lyon
- Research Site - Villejuif
- Research Site - Meldola
- Research Site - Naples
- Research Site - Ravenna
- Research Site - Roma
- Research Site - Amsterdam
- Research Site - Lisbon
- Research Site - Porto
Tennessee
- Research Site - Chattanooga
- Research Site - Nashville
Michigan
- Research Site - Detroit
New York
- Research Site - New York
North Carolina
- Research Site - Chapel Hill
Rhode Island
- Research Site - Providence
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2018-04-24 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03530397
The ClinicalTrials.gov registry entry for NCT03530397 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 401 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Selected Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03530397 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Tennessee, Michigan.
Frequently Asked Questions
What is clinical trial NCT03530397 about?
NCT03530397 is a clinical study titled "A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors". The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.
What is the current status of trial NCT03530397?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 401 participants. The study started on 2018-04-24. Estimated completion is 2025-12-30.
What conditions does trial NCT03530397 study?
This clinical trial studies the following conditions: Selected Advanced Solid Tumors.
What interventions are being tested in trial NCT03530397?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Pemetrexed (DRUG), MEDI5752 (BIOLOGICAL), Paclitaxel or Nab-Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03530397?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03530397 being conducted?
This trial has 20 study locations across Michigan, New York, North Carolina, Rhode Island, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.